Research status of bone tissue-derived exosomes on bone metabolism

doi:10.3877/cma.j.issn.2096-0263.2018.05.010

Abstract

Abstract:

Osteoporosis is a common and frequently occurring disease in the elderly. Studies found that the bone derived cells can also secrete the exsomes packaging and delivering a variety of active substances, such as protein, miRNAs, various active factors, carrying out the exchange of material and information between cells. According to the characteristics and contents of bone-derived exosomes, they can be used to regulate bone formation and bone resorption balance, even as carrier of biological or gene therapy, this kind of research may provide a new idea for the prevention and treatment of osteoporosis in the elderly.

Key words: Osteoporosis, Exosomes, Osteogenesis, Bone resorption

Shilei Wu, Yong Liu, Zengwu Shao, Qing Tian. Research status of bone tissue-derived exosomes on bone metabolism[J]. Chinese Journal of Geriatric Orthopaedics and Rehabilitation(Electronic Edition), 2018, 04(05): 308-311.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhlngkykfdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2096-0263.2018.05.010

https://zhlngkykfdzzz.cma-cmc.com.cn/EN/Y2018/V04/I05/308

Figures/Tables 1

References 39

[1]	North Ameirican Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause [J]. Menopause, 2010, 17(2): 242-255.
[2]	Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 [J]. J Bone Miner Res, 2007, 22(3): 465-475.
[3]	Gehlbach SH, Avrunin JS, Puleo E, et al. Fracture risk and antiresorptive medication use in older women in the USA [J]. Osteoporos Int, 2007, 18(6): 805-810.
[4]	Soekmadji C, Russell PJ, Nelson CC. Exosomes in prostate cancer: putting together the pieces of a puzzle [J]. Cancers (Basel), 2013, 5(4): 1522-1544.
[5]	Vlassov AV, Magdaleno S, Setterquist R, et al. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials [J]. Biochim Biophys Acta, 2012, 1820(7): 940-948.
[6]	Deng LL, Wang YP, Peng Y, et al. Osteoblast-derived microvesicles: A novel mechanism for communication between osteoblasts and osteoclasts [J]. Bone, 2015, 79: 37-42.
[7]	Huynh N, Vonmoss L, Smith D, et al. Characterization of regulatory extracellular vesicles from osteoclasts [J]. J Dent Res, 2016, 95(6): 673-679.
[8]	Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends [J]. J Cell Biol, 2013, 200(4): 373-383.
[9]	Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more [J]. Trends Cell Biol, 2009, 19(2): 43-51.
[10]	Runz S, Keller S, Rupp C, et al. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM [J]. Gynecol Oncol, 2007, 107(3): 563-571.
[11]	Pols MS, Klumperman J. Trafficking and function of the tetraspanin CD63 [J]. Exp Cell Res, 2009, 315(9): 1584-1592.
[12]	Sun W, Zhao C, Li Y, et al. Osteoclast-derived microRNA-containing exosomes selectively inhibit osteoblast activity [J]. Cell Discov, 2016, 2(2): 16015.
[13]	Li D, Liu J, Guo B, et al. Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation [J]. Nat Commun, 2016, 7(7): 10872.
[14]	Deng L, Wang Y, Peng Y, et al. Osteoblast-derived microvesicles: A novel mechanism for communication between osteoblasts and osteoclasts [J]. Bone, 2015, 79: 37-42.
[15]	Antonyak MA, Li B, Boroughs LK, et al. Cancer cell-derived microvesicles induce transformation by transferring tissue transglutaminase and fibronectin to recipient cells [J]. Proc Natl Acad Sci U S A, 2011, 108(12): 4852-4857.
[16]	Xie Y, Chen Y, Zhang L, et al. The roles of bone-derived exosomes and exosomal microRNAsin regulating bone remodeling [J]. J Cell Mol Med, 2017, 21(5): 1033-1041.
[17]	Qin YH, Wang L, Gao ZL, et al. Bone marrow stromal/stem cell-derived extracellular vesicles regulate osteoblast activity and differentiation in vitro and promote bone regeneration in vivo [J]. Sci Rep, 2016, 6(6): 21961.
[18]	Zhao LM, Jiang S, Hantash BM. Transforming growth factor beta 1 induces osteogenic differentiation of murine bone marrow stromal cells [J]. Tissue Eng Part A, 2010, 16(2): 725-733.
[19]	Luther G, Wagner ER, Zhu GH, et al. BMP-9 induced osteogenic differentiation of mesenchymal stem cells: molecular mechanism and therapeutic potential [J]. Curr Gene Ther, 2011, 11(3): 229-240.
[20]	Narayanan R, Huang CC, Ravindran S. Hijacking the cellular mail: exosome mediated differentiation of mesenchymal stem cells [J]. Stem Cells Int, 2016: 3808674.
[21]	Cui YZ, Luan J, Li HY, et al. Exosomes derived from mineralizing osteoblasts promote ST2 cell osteogenic differentiation by alteration of microRNA expression [J]. FEBS Lett, 2016, 590(1): 185-192.
[22]	Ekstrom K, Omar O, Graneli C, et al. Monocyte exosomes stimulate the osteogenic gene expression of mesenchymal stem cells [J]. PLoS One, 2013, 8(9): 75227.
[23]	Omar MO, Graneli C, Ekstrom K, et al. The stimulation of an osteogenic response by classical monocyte activation [J]. Biomaterials, 2011, 32(32): 8190-8204.
[24]	Egea V, Zahler S, Rieth N, et al. Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/beta-catenin signaling [J]. Proc Natl Acad Sci U S A, 2012, 109(6): E309-E316.
[25]	Wei J, Li H, Wang S, et al. let-7 enhances osteogenesis and bone formation while repressing adipogenesis of human stromal/mesenchymal stem cells by regulating HMGA2 [J]. Stem Cells Dev, 2014, 23(13): 1452-1463.
[26]	Zhang Y, Xie RL, Croce CM, et al. A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2 [J]. Proc Natl Acad Sci USA, 2011, 108(24): 9863-9868.
[27]	Li Z, Hassan MQ, Volinia S, et al. A microRNA signature for a BMP2-induced osteoblast lineage commitment program [J]. Proc Natl Acad Sci U S A, 2008, 105(37): 13906-13911.
[28]	Xu JF, Yang GH, Pan XH, et al. Altered MicroRNA expression profile in exosomes during osteogenic differentiation of human bone Marrow-Derived mesenchymal stem cells [J]. PLoS One, 2014, 9(12): e114627.
[29]	Huang J, Zhao L, Xing LP, et al. MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation [J]. Stem Cells, 2010, 28(2): 357-364.
[30]	Hwang S, Park SK, Lee HY, et al. miR-140-5p suppresses BMP2-mediated osteogenesis in undifferentiated human mesenchymal stem cells [J]. FEBS Lett, 2014, 588(17): 2957-2963.
[31]	Qin Y, Sun R, Wu C, et al. Exosome: A novel approach to stimulate bone regeneration through regulation of osteogenesis and angiogenesis [J]. Int J Mol Sci, 2016, 17(5): 712.
[32]	Kim YJ, Bae SW, Yu SS, et al. miR-196a regulates proliferation and osteogenic differentiation in mesenchymal stem cells derived from human adipose tissue [J]. J Bone Miner Res, 2009, 24(5): 816-825.
[33]	Hassan MQ, Maeda Y, Taipaleenmaki H, et al. miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells [J]. J Biol Chem, 2012, 287(50): 42084-42092.
[34]	Chen C, Cheng P, Xie H, et al. MiR-503 regulates osteoclastogenesis via targeting RANK [J]. J Bone Miner Res, 2014, 29(2): 338-347.
[35]	James AW. Review of signaling pathways governing MSC osteogenic and adipogenic differentiation [J]. Scientifica (Cairo), 2013: 684736.
[36]	Cheng P, Chen C, He HB, et al. miR-148a regulates osteoclastogenesis by targeting v-maf musculoaponeurotic fibrosarcoma oncogene homolog B [J]. J Bone Miner Res, 2013, 28(5): 1180-1190.
[37]	Wang X, Guo B, Li Q, et al. miR-214 targets ATF4 to inhibit bone formation [J]. Nat Med, 2013, 19(1): 93-100.
[38]	Zhao C, Sun W, Zhang P, et al. miR-214 promotes osteoclastogenesis by targeting Pten/PI3k/Akt pathway [J]. RNA Biol, 2015, 12(3): 343-353.
[39]	渠海波，张朝，吴刚.骨质疏松的研究进展[J].包头医学院学报, 2013, 29(3): 119-121.

细胞来源	外泌体标记	外泌体包含物
成骨细胞前体细胞	EpCAM，CD63	低含量RANK
成骨细胞	EpCAM，CD63	高含量RANK，EphrinA2
破骨细胞前体细胞	flotillin2	蛋白质：EIFfamily，PP1C，OPG，PABP，RANKL，TRAP；mRNA：AC1N1，DDX6，DGKA，DDK2，Lsm2，RPS2，Xsox17；miRAN：let-7，miR-30d-5p，miR-133b-3p，miR-140-3p，miR-335-3p，miR-677-3p，miR-378b，miR-503-3p
破骨细胞	CD13，CD29，CD44	蛋白质：ADAM17，NFκB1，BMP9，TGFβ1；CD73，CD105；miRNA：let-7，miR-135b，miR-148a，miR-181a，miR196a，miR-199b，miR-218，miR-221，miR-885-5p

细胞来源	外泌体标记	外泌体包含物
成骨细胞前体细胞	EpCAM，CD63	低含量RANK
成骨细胞	EpCAM，CD63	高含量RANK，EphrinA2
破骨细胞前体细胞	flotillin2	蛋白质：EIFfamily，PP1C，OPG，PABP，RANKL，TRAP；mRNA：AC1N1，DDX6，DGKA，DDK2，Lsm2，RPS2，Xsox17；miRAN：let-7，miR-30d-5p，miR-133b-3p，miR-140-3p，miR-335-3p，miR-677-3p，miR-378b，miR-503-3p
破骨细胞	CD13，CD29，CD44	蛋白质：ADAM17，NFκB1，BMP9，TGFβ1；CD73，CD105；miRNA：let-7，miR-135b，miR-148a，miR-181a，miR196a，miR-199b，miR-218，miR-221，miR-885-5p

Please choose a citation manager

Content to export